Paradigm Biopharmaceuticals says the FDA has endorsed key elements of its proposed phase III knee osteoarthritis trial.

clearance from the US Food and Drug Administration (FDA) to offer its MIMneuro software with Centiloid scaling in patients ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

The company published trial design and preliminary data from the adaptive DBS algorithm for personalised therapy in Parkinson ...

BD (Becton, Dickinson and Company) , a leading global medical technology company, announced the commercial release of the BD Neopaktm XtraFlowtm Glass Prefillable Syringe and the latest capacity ...

IGC Pharma, Inc. ("IGC Pharma" or the "Company") today announced data that reinforces the therapeutic potential of IGC-AD1 as a disease-modifying treatment for Alzheimer's disease. The data highlights ...

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...